Defendant

Teva Pharmaceuticals Industries, Ltd.

1 case as defendant.

Cases
1
Active
0
1 closed
Filed
2016
Top venue
D. New Jersey
1 case

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

judgment (invalidity); affirmed on appeal
Docket:
2:16-cv-07721 (JLL)(JAD); 2:17-cv-00864; 2:17-cv-02877; 2:17-cv-05100; 2:18-cv-09880
Filed:
2016-11-26
Terminated:
2020-06-26
Patents:9192570946874795611779629965977583810085937
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Teva Pharmaceuticals USA, Inc.Δ Teva Pharmaceuticals Industries, Ltd.

Adapt and Opiant sued Teva in D.N.J. asserting NARCAN naloxone nasal spray patents. The district court found the asserted patents invalid for obviousness on June 5, 2020, with judgment entered June 26, 2020; the Federal Circuit affirmed on Feb. 10, 2022. The '570 patent was not asserted but was cited as prior art (Wyse). Consolidated/related docket numbers included 2:17-cv-00864, 2:17-cv-02877, 2:17-cv-05100, 2:18-cv-09880; related Perrigo action 2:18-cv-15287.